Published in Medical Letter on the CDC and FDA, January 8th, 2006
As previously reported, the Navy's investigational new drug application (IND) to conduct this trauma trial is currently on hold at the FDA, primarily due to the agency's concerns about the risk-benefit profile in this patient population.
At the meeting, military and academic trauma experts from the Navy's RESUS advisory board addressed the FDA's concerns...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.